Ostentus Therapeutics, Inc. is a pre-clinical biotechnology company investigating the activity, efficacy, and safety of its novel natural compounds in the treatment of different types of cancer and leukemia. Ostentus Therapeutics’ mission is to advance the study and development of its multicancer fighting natural compounds and demonstrate their superior efficacy and safety in humans, through rigorous pharmacological testing. Currently available options for cancer treatment involve surgical removal and radiation treatment followed by systemic chemotherapy treatment. The primarily available chemotherapeutic agents are antimetabolites (e.g., methotrexate), DNA-interactive agents (e.g., cisplatin, doxorubicin), anti-tubulin agents (e.g., taxanes), hormones, molecular targeting agents and immunotherapeutics.